Copper Peptides Are Everywhere: What GHK-Cu Actually Does in Skin Research

By BioLabs Research · October 4, 2026 · 5 min read

That electric-blue serum on your For You page has a 50-year research history. Here is what it says, and what it doesn't.

How a 1970s lab finding became a beauty trend

Copper peptides did not start on TikTok. They started in a liver lab.

In 1973, biochemist Loren Pickart and co-author M. M. Thaler reported a small factor in human serum that seemed to help aging liver tissue behave more like younger tissue (Pickart & Thaler, Nature New Biology, 1973). A few years later, researchers identified the factor as a tripeptide: three amino acids, glycine, histidine and lysine, now shortened to GHK (Schlesinger et al., Experientia, 1977). Follow-up work showed that GHK binds tightly to copper ions. The copper-bound form is the one you now see on labels as GHK-Cu or "copper tripeptide-1" (Pickart et al., Journal of Cellular Physiology, 1980).

For decades this was a niche topic in cell biology and cosmetic chemistry. Then it found an audience. NPR reported in September 2026 that copper peptides had become "the darling of social media skin care hacks," and that the trend had moved beyond creams and serums into uses that have no published human safety data (NPR, Sept. 7, 2026). USA Today ran its own explainer on what GHK-Cu is and what it can realistically do (USA Today).

What GHK is, in plain terms

GHK is a very small peptide that the body makes on its own. According to reviews by Pickart and colleagues, it is found in human plasma, saliva and urine. The same reviews report that plasma levels fall with age, from about 200 ng/mL at age 20 to about 80 ng/mL by age 60 (Pickart et al., BioMed Research International, 2015).

That age-related decline is a big reason the molecule gets marketed with age-related claims. Lower levels in older people show a correlation, though. They do not show that adding GHK back reverses anything. Keep that distinction in mind whenever you see the claim on social media.

What the skin research actually looked at

Most published GHK-Cu work falls into three buckets.

1. Cell and tissue studies. In lab dishes and tissue models, researchers have reported that GHK-Cu affects collagen, elastin and other parts of the skin's support structure, the extracellular matrix. A 2008 review by Pickart lists effects on collagen and elastin synthesis, enzymes that remodel tissue, and the growth of fibroblasts and keratinocytes, the two main skin-cell types studied (Pickart, J. Biomater. Sci. Polym. Ed., 2008).

2. Wound and tissue-repair models. The same reviews describe faster wound closure in several animal models, including rats, mice, pigs and dogs (Pickart et al., 2015). These are research models, not evidence that any product treats wounds in people, and we make no such claim.

3. Gene-expression data. A 2018 review argues, based on public gene-expression databases, that GHK is associated with changes in the activity of thousands of human genes, many of them tied to tissue repair and antioxidant pathways (Pickart & Margolina, International Journal of Molecular Sciences, 2018). The finding is interesting, but it is also easy to oversell. A change in gene activity in a database analysis is a hypothesis generator. It does not show what happens in a person's face.

One honest caveat: much of the review literature on GHK-Cu comes from the molecule's discoverer and from authors listed under a skincare research company's address (see the affiliation lines on both reviews linked above). That does not make the work wrong. It does mean independent replication carries extra weight.

What about the creams and serums?

This is where the evidence is closest to everyday life. NPR noted that topical copper peptide serums and creams "have been on the market for decades and studied in human trials." Those trials are "generally small" and funded by the cosmetic industry, the outlet reported, and they report improvements in skin thickness, elasticity and wrinkles (NPR, 2026).

Harvard Health takes a similar line on peptides in general. Some peptides in eye creams that are thought to stimulate collagen "could possibly help skin appear more youthful," it says, but strong evidence for many of the peptides promoted online is "largely absent" (Harvard Health Publishing).

So the fair summary is that there is real but modest evidence for cosmetic use, mostly from small, industry-funded studies.

Why "copper peptide serum" exploded now

Three things seem to have collided:

• Search and social momentum. Glossy, citing the market-research firm Spate, reported that interest in "peptide therapy" grew 281% year over year on Google, 459% on TikTok and 412% on Instagram as of early April 2026 (Glossy).
• A visual hook. GHK-Cu solutions are a striking blue, which is made for short-form video.
• Brand launches. The same Glossy piece describes a new wave of peptide product launches across skin and hair care.

Cosmetic product vs. research-grade material

This is the gap most videos skip.

A cosmetic copper peptide serum is a finished consumer product. Under US law, a product's category depends on its intended use. FDA explains that cosmetics are meant for "cleansing, beautifying, promoting attractiveness, or altering the appearance," while products intended to affect the structure or function of the body are drugs (FDA: Is It a Cosmetic, a Drug, or Both?). A serum's ingredient list tells you what is in the bottle. It usually does not tell you how much GHK-Cu it contains, or whether that amount matches any published study.

Research-grade material is something else. It is a characterized compound supplied to laboratories, documented with identity and purity data such as HPLC and mass-spectrometry results, and labeled for research use only. These are research materials, not drugs or supplements, and not cosmetics.

The useful takeaway for readers is that "GHK-Cu" on a serum label and "GHK-Cu" on a lab certificate of analysis answer different questions.

What we know / What we don't know

What we know

• GHK was described in the 1970s and binds copper (Pickart & Thaler, 1973; Pickart et al., 1980).
• Cell, tissue and animal studies report effects on skin-matrix proteins and wound models (Pickart, 2008).
• Topical products have been sold for decades and tested in small, mostly industry-funded trials (NPR, 2026).

What we don't know

• How results in small cosmetic trials hold up in larger, independent studies.
• How much of the gene-expression story translates to living human skin.
• Whether routes other than topical are safe or effective. NPR reported there is no published human data for them.

Related reading: What Published Research Has Examined: A Reading Guide for Four Studied Compounds

---

Sources are linked inline. This article is for general information about published research and media coverage. It is not medical advice. BioLabs Research supplies research materials, not drugs or supplements, for laboratory research use only.

For research use only. Not for human or veterinary use. Not a drug, food, or cosmetic.

This summary is for research-community awareness only and is not legal advice.